RARA CRAFT DATABASE for FDA Medical Devices

FDA Device Decisions, November 2025: Focused Ultrasound for Facet Joint Pain, Two De Novo Grants and Two Original PMAs

日本語版

One of FDA's two De Novo grants in November 2025 went to Neurolyser XR (DEN250015), which uses high intensity focused ultrasound to thermally ablate the medial branch nerves of the lumbar facet joints from outside the body. It is for chronic facet-mediated low back pain of at least six months, with the diagnosis confirmed by a positive response to medial branch block.

November's 510(k) count was 203, well below October's 304. PMA supplements, at 78, were also far below October's 226.

Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 203 510(k)s in November 2025, granted 2 De Novo requests and approved 2 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.

Counts by pathway

November 2025 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.

PathwayNovember 2025October 2025November 2024
510(k)203304258
De Novo243
PMA (original)213
PMA supplement78226213

Records held in RA Craft Database, decisions through August 31, 2026.

510(k) clearances were 101 fewer than in October and below November 2024 (258). PMA supplements were about a third of both comparison months.

The busiest product codes

November's 510(k)s spread across 141 product codes. GEX (powered laser surgical instrument) led with 11, followed by IYN (system, imaging, pulsed doppler, ultrasonic) with 6, HRS (plate, fixation, bone) with 5, and GEI (electrosurgical, cutting & coagulation & accessories) and LLZ (system, image processing, radiological) with 4 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.

De Novo: two classifications

November's two De Novo grants, both Class II, with the classification names and regulation numbers from each Classification Order:

  • Neurolyser XR (DEN250015, FUSMobile, Inc.): High intensity focused ultrasound system for peripheral neural tissue ablation (21 CFR 882.4420)
  • MuReva OM™ (DEN240077, MuReva Phototherapy, Inc.): Intraoral phototherapy device (21 CFR 872.5595)

"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.

MuReva OM delivers light inside the mouth during radiation treatment to lower the severity of radiation-induced oral mucositis in adults receiving radiation to less than 75% of the oral cavity, with or without chemotherapy.

Original PMAs: two approvals

  • OncoMate® MSI Dx Analysis System (P240026, Promega Corporation): a companion diagnostic that identifies microsatellite stable endometrial carcinoma for pembrolizumab with lenvatinib (product code SFL)
  • IsoPSA Assay (P200048, Cleveland Diagnostics, Inc.): combines prostate-specific antigen (PSA) measurements from partitioned plasma into an index that aids detection of high-grade prostate cancer in men being considered for biopsy (QRF)

November also brought 78 PMA supplements, which cover changes to already approved PMA devices among other things.

Three devices worth a closer read

1. Neurolyser XR (DEN250015, De Novo). Without an incision, focused ultrasound heats and ablates the medial branch nerves from L1 to L5. Its six special controls include in vivo performance testing (effects on target and non-target tissue), non-clinical testing of acoustic output, focal temperature, positioning accuracy and cavitation safety, and software verification.

2. IsoPSA Assay (P200048, PMA). For men 50 and older with total PSA of 4 to 10 ng/mL whom a urologist is considering for biopsy, the test aids detection of high-grade prostate cancer (Grade Group 2 or higher). According to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, sensitivity at an index of 6.0 or below was 93.8% in the prospective multicenter pivotal study. The test received Breakthrough Device designation in 2019. A post-approval study of at least 250 African American men is a condition of approval.

3. OncoMate® MSI Dx Analysis System (P240026, PMA). According to the SSED, the system was earlier cleared by 510(k) (K200129) to help identify possible Lynch syndrome in colorectal cancer. This time it was approved by PMA as a companion diagnostic to select endometrial cancer patients for pembrolizumab with lenvatinib. The same product took a different pathway once the indication changed.

Compare the three devices

Open DEN250015, P200048 and P240026, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.

Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles